Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Operations (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Cash from Operations for 4 consecutive years, with 5001000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 92.12% to 5001000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 166775000.0 through Dec 2025, up 37.48% year-over-year, with the annual reading at 166775000.0 for FY2025, 37.48% up from the prior year.
  • Cash from Operations for Q4 2025 was 5001000.0 at Phathom Pharmaceuticals, up from 14115000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 5001000.0 in Q4 2025, with the low at 84930000.0 in Q1 2025.
  • Average Cash from Operations over 4 years is 44853437.5, with a median of 42419000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations tumbled 218.56% in 2024, then soared 92.12% in 2025.
  • Over 4 years, Cash from Operations stood at 41041000.0 in 2022, then dropped by 6.72% to 43797000.0 in 2023, then crashed by 44.89% to 63456000.0 in 2024, then skyrocketed by 92.12% to 5001000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 5001000.0, 14115000.0, and 62729000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.